Hepatitis Monthly

Published by: Kowsar

Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients

Byung Kook Kim 1 , Soon Young Ko 1 , So Young Kwon 1 , * , Eugene Park 1 , Jeong Han Kim 1 , Won Hyeok Choe 1 and Chang Hong Lee 1
Authors Information
1 Department of Internal Medicine, Konkuk University School of Medicine, Seoul, 143-729, Korea
Article information
  • Hepatitis Monthly: March 01, 2013, 13 (4); e6056
  • Published Online: March 31, 2013
  • Article Type: Research Article
  • Received: May 13, 2012
  • Revised: May 24, 2012
  • Accepted: May 26, 2012
  • DOI: 10.5812/hepatmon.6056

To Cite: Kim B K, Ko S Y, Kwon S Y, Park E, Kim J H, et al. Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients, Hepat Mon. 2013 ; 13(4):e6056. doi: 10.5812/hepatmon.6056.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Chien RN, Liaw YF. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008; 22(6): 1081-92[DOI][PubMed]
  • 2. Buti M, Esteban R. Drugs in development for hepatitis B. Drugs. 2005; 65(11): 1451-60[PubMed]
  • 3. Lee HS, Chung YH, Lee K, Byun KS, Paik SW, Han JY, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2006; 43(5): 982-8[DOI][PubMed]
  • 4. Lim SG, Leung N, Hann HW, Lau GK, Trepo C, Mommeja-Marin H, et al. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2008; 27(12): 1282-92[DOI][PubMed]
  • 5. Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2007; 45(5): 1172-8[DOI][PubMed]
  • 6. Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology. 2007; 46(4): 1041-8[DOI][PubMed]
  • 7. Kim MH, Kim KA, Lee JS, Lee HW, Kim HJ, Yun SG, et al. [Efficacy of 48-week clevudine therapy for chronic hepatitis B]. Korean J Hepatol. 2009; 15(3): 331-7[DOI][PubMed]
  • 8. Ko SY, Kwon SY, Choe WH, Kim BK, Kim KH, Lee CH. Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study. Antivir Ther. 2009; 14(4): 585-90[PubMed]
  • 9. Lau GK, Leung N. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J Hepatol. 2010; 16(3): 315-20[DOI][PubMed]
  • 10. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol. 2009; 51(4): 787-91[DOI][PubMed]
  • 11. Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology. 2009; 49(6): 2080-6[DOI][PubMed]
  • 12. Tak WY, Park SY, Cho CM, Jung MK, Jeon SW, Kweon YO, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol. 2010; 53(2): 261-6[DOI][PubMed]
  • 13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661-2[DOI][PubMed]
  • 14. Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther. 2005; 10(3): 441-9[PubMed]
  • 15. Niai D. Division of AIDS table for grading the severity of adult and pediatric adverse events. Journal [serial on the Internet]. 2004; : 1-21
  • 16. Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry. 2009; 80(8): 832-8[DOI][PubMed]
  • 17. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat. 2012; 19(6): 377-86[DOI][PubMed]
  • 18. Shin SR, Yoo BC, Choi MS, Lee DH, Song SM, Lee JH, et al. A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naive patients with chronic hepatitis B. Hepatol Int. 2011; 5(2): 664-70[DOI][PubMed]
  • 19. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009; 136(2): 486-95[DOI][PubMed]
  • 20. Kim HJ, Park DI, Park JH, Cho YK, Sohn CI, Jeon WK, et al. Comparison between clevudine and entecavir treatment for antiviral-naive patients with chronic hepatitis B. Liver Int. 2010; 30(6): 834-40[DOI][PubMed]
  • 21. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359(23): 2442-55[DOI][PubMed]
  • 22. Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol. 2010; 84(9): 4494-503[DOI][PubMed]
  • 23. Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther. 2007; 29(12): 2635-53[DOI][PubMed]
  • 24. Scruggs ER, Dirks Naylor AJ. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology. 2008; 82(2): 83-8[DOI][PubMed]
  • 25. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995; 333(17): 1099-105[DOI][PubMed]
  • 26. Lee HS, Yoo BC, Lee KS, Kim JH, Um SH, Ryu SH, et al. Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy. J Gastroenterol. 2011; 46(3): 410-4[DOI][PubMed]
  • 27. Creatine kinase elevations during 4 years of continuous telbivudine treatment are transient and not predictive of uncommonly observed muscle related symptoms [abstract]. 60th Annual Meeting of the American Association for the Study of the Liver Diseases (AASLD).
  • 28. Kim BK, Oh J, Kwon SY, Choe WH, Ko SY, Rhee KH, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol. 2009; 51(4): 829-34[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments